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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most
common cause of dementia. Accumulating experimental evidence shows the important
linkage between tumor necrosis factor-α (TNF) and AD, but the exact role of TNF in
AD is still not completely understood. Although TNF-inhibitors are successfully used
for treating several diseases, total inhibition of TNF can cause side effects, particularly
in neurological diseases. This is attributed to the opposing roles of the two TNF
receptors. TNF receptor 1 (TNFR1) predominantly mediates inflammatory and pro-
apoptotic signaling pathways, whereas TNF receptor 2 (TNFR2) is neuroprotective and
promotes tissue regeneration. Therefore, the specific activation of TNFR2 signaling,
either by directly targeting TNFR2 via TNFR2 agonists or by blocking TNFR1 signaling
with TNFR1-selective antagonists, seems a promising strategy for AD therapy. This mini-
review discusses the involvement of TNFR2 and its signaling pathway in AD and outlines
its potential application as therapeutic target. A better understanding of the function of
TNFR2 may lead to the development of a treatment for AD.
Keywords: tumor necrosis factor, Alzheimer’s disease, neurodegeneration, neuroprotection, agonists,
antagonists
INTRODUCTION
The pleiotropic pro-inflammatory cytokine tumor necrosis factor-α (TNF), known as a member of
the TNF superfamily of ligands, is a master regulator of the innate and adaptive immune system.
TNF plays a vital role in the initiation and orchestration of inflammation and immunity (Aggarwal,
2003; Apostolaki et al., 2010; Fischer and Maier, 2015), and is potentially a key player in several
neurodegenerative disorders, including Alzheimer’s disease (AD) (McAlpine and Tansey, 2008).
Alzheimer’s disease is an age-related neurodegenerative disorder associated with severe cognitive
impairment such as memory deficits, deterioration of visuospatial skills and executive dysfunction.
Its neuropathological hallmarks include both positive and negative features. Positive lesions consist
of amyloid plaques, neurofibrillary tangles, neuropil threads, tau protein hyperphosphorylation,
and glial activation. Negative lesions include losses of neurons, neuropil, and synaptic elements.
Besides the well-known pathological characteristics mentioned above, neuroinflammation has been
considered a major contributor to AD, in which TNF is an important mediator (McAlpine and
Tansey, 2008).
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Tumor necrosis factor is expressed as a 26-kDa monomeric
type II transmembrane protein (tmTNF) that can be cleaved
to release a 17-kDa soluble monomeric protein (solTNF)
by the matrix metalloprotease TNF converting enzyme
(TACE/ADAM17) (Aggarwal, 2000; Idriss and Naismith,
2000). TNF binds to two cognate receptors, the 55-kDa TNF
receptor 1 (TNFR1, p55, TNFRSF1A) and the 75-kDa TNF
receptor 2 (TNFR2, p75, TNFRSF1B), that mediate a variety
of cellular responses. In general, TNFR1 predominantly exerts
pro-inflammatory effects and TNFR2 is neuroprotective and
promotes tissue homeostasis and regeneration. The identification
of TNF expression around amyloidogenic plaques in human AD
post-mortem brain tissue was the first indication of its possible
involvement in AD (Dickson, 1997). At the protein level, elevated
serum and plasma levels of TNF have been detected in patients
with AD (Fillit et al., 1991; Bruunsgaard et al., 1999; Collins
et al., 2000; Alvarez et al., 2007; Tan et al., 2007). Moreover,
overproduction of inflammatory mediators in the AD brain
occurs when microglia become chronically activated. It has been
suggested that resident microglia fail to efficiently phagocytose
amyloid beta (Aβ) because of elevated levels of proinflammatory
cytokines, including TNF (Koenigsknecht-Talboo and Landreth,
2005). Besides, cell culture studies showed that TNF increased
apoptosis of neurons treated with Aβ (Blasko et al., 1997) and
affected Aβ production (Blasko et al., 1999, 2000). Furthermore,
at the genetic level, three TNF polymorphisms were found to
be associated with AD (Collins et al., 2000). For example, the
TNF G308A promoter polymorphisms was found to increase the
risk of AD in certain people (Kang et al., 2015; Wang, 2015). As
TNFR2 activation has recently emerged as a potential therapeutic
approach for neurodegeneration (Dong et al., 2016), we will
here introduce TNFR2, focusing on the interrelation of TNFR2
and AD, and summarize a potential therapeutic strategy to
specifically target TNFR2 in AD.
TNFR2 EXPRESSION AND STRUCTURE
Tumor necrosis factor receptor 1 is ubiquitously expressed
in virtually all cell types and tissues, and its activation can
be induced by either solTNF or tmTNF, with a preference
for solTNF. TNFR2 is predominately expressed in cells of
the immune system, especially regulatory T (Treg) cells, and
by endothelial cells, and preferentially binds tmTNF (Grell,
1995; Grell et al., 1998). TNFR1 and TNFR2 are single-pass
transmembrane glycoproteins with 28% homology mainly in
the extracellular domain, that is comprised of four cysteine-
rich motif (Locksley et al., 2001). However, the intracellular
domains of the TNF receptors are largely unrelated, lacking
homologous sequences (Lewis et al., 1991), suggesting that
different signaling functions originate from the two distinct
receptors. TNFR1 contains an intracellular death domain (DD)
that binds TNFR1-associated death domain protein (TRADD)
of Fas-associated death domain (FADD), primarily involved
in signaling for cell death. While TNFR2 does not contain
a cytoplasmic DD, it interacts with TNF-associated factor 2
(TRAF2), and mainly yields cell survival (Wajant et al., 2003).
TNFR2 consists of 439 amino acids, with the first 235 amino
acids forming the extracellular domain, 30 amino acids forming
the transmembrane domain, and 174 amino acids forming the
cytoplasmic domain with a TRAF2 binding site. TRAF2 can
bind TRAF1, TRAF3, inhibitor of apoptosis protein 1 (cIAP1)
and inhibitor of apoptosis protein 2 (cIAP2) (Rothe et al., 1994,
1995b).
TNFR2 SIGNALING
Tumor necrosis factor signaling can elicit various cellular
responses through TNFR1 and TNFR2 depending on a variety
of factors including the cellular metabolic state and the
presence of the adaptor proteins. In fact, the differences in
the intracellular signaling pathways such as nuclear factor
kappa-B (NF-κB), p38, c-jun N-terminal kinase (JNK), and
the ceramide/sphingomyelinase signaling pathway, result in
multifarious processes including inflammation, proliferation, cell
migration, apoptosis, and necrosis (Eissner et al., 2000, 2004;
Harashima et al., 2001; Ware, 2005). TNFR2-mediated signaling
activates inflammatory and pro-survival signaling pathways via
interaction with adaptor proteins of TRAF1 and TRAF2, and
in turn, also the cIAPs and the NF-κB pathway (Rothe et al.,
1994, 1995a; Rao et al., 1995) (Figure 1). TNFR2 can also activate
the phosphatidyl inositol (PI) 3-kinase/Akt pathway to promote
cell survival and proliferation (Marchetti et al., 2004; Dolga
et al., 2008; Fischer et al., 2011). In addition, there could be a
cross talk between TNFR1 and TNFR2 because of the central
role that TRAF2, TRAF1, and cIAP play in both TNFR1 and
TNFR2 signaling pathways (Naudé et al., 2011). For instance,
it was shown that the depletion of TRAF2 caused by TNFR2
activation accelerates the activation of TNFR1-dependent caspase
8 (Wang et al., 1998; Fotin-Mleczek et al., 2002; Li et al., 2002).
In general, TNFRs cross talk is elusive and regulated by both
the physiological environment and signaling kinetics between
TNFR1 and TNFR2.
TNF RECEPTORS IN ALZHEIMER’S
DISEASE
Mounting evidence convincingly shows that TNF expression
is increased in AD by various methods and means, including
genetic (Collins et al., 2000), protein expression (Álvarez
et al., 2007) and histological (Zhao et al., 2003) approaches.
Considering that TNFR1 exerts inflammatory and pro-apoptotic
functions, whereas TNFR2 has a neuroprotective function, it is
of utmost importance to define the expression of both receptors
in AD. For instance, studies in human post-mortem AD brain
tissues have demonstrated that TNFR1 levels are increased while
TNFR2 levels are decreased (Zhao et al., 2003; Cheng et al.,
2010). Furthermore, Cheng et al. (2010) showed that in the AD
brain, TNF had a higher likelihood to bind to TNFR1 than to
TNFR2, which might explain the prominent role of TNFR1 in
the pathophysiology of AD. Strikingly, deletion of TNFR2 in an
AD mouse model exacerbated AD pathology through TNFR1
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FIGURE 1 | Molecular signaling pathway of TNFR2. The interaction of the membrane form of TNF with TNFR2 promotes cell survival through the activation of the
complex signaling cascade. AIP1, ASK interacting protein 1; Akt, serine–threonine kinase; ASK1, apoptosis signal-regulating kinase 1; cFLIP, caspase-8 homolog
FLICE-inhibitory protein; cIAP, cellular inhibitor of apoptosis protein; FADD, Fas-associated death domain protein; IKK, IκB kinase; IκBα, inhibitor of kappa B; JNK,
c-Jun N-terminal kinase; NFκB, nuclear factor kappa B; MAPKs, phosphorylate mitogen-activated kinase; MKK, mitogen-activated protein kinase kinase; NIK,
NFκB-inducing kinase; PI3K, phosphoinositide 3-kinases; RIP, receptor interacting protein; TRADD, TNF receptor-associated death domain; TRAF, TNF
receptor-associated factor.
(Jiang et al., 2014). In this same study, a later overexpression
of TNFR2 counteracted the aggravation of the disease (Jiang
et al., 2014). This finding reinforces a neuroprotective function
of TNFR2 in AD pathology. Furthermore, in a mouse model of
acute retinal ischemia, Fontaine et al. (2002) demonstrated that,
after inducing retinal damage, mice lacking TNFR1 showed a
significant reduction in neurodegeneration while mice lacking
TNFR2 showed a significant increase in neurodegeneration.
Similarly, deletion of TNFR1 in an AD mouse model resulted in a
reduction in the generation of Aβ plaques and an enhancement
in learning and memory (He et al., 2007; Olleros et al., 2010),
indicating the contribution of TNFR1 to neurodegeneration.
Lastly, a recent study demonstrated in AD mouse models that
abrogation of TNFR1 results in decreased brain inflammation
and in an improvement of amyloidosis and blood–brain barrier
integrity (Steeland et al., 2018).
Altogether, these results support the hypothesis that increased
expression of TNFR1 aggravates AD pathology, whereas TNFR2
is able to prevent it. Therefore, TNFR1 and TNFR2 represent
promising therapeutic targets for the treatment or prevention
of AD.
TARGETING TNF AND TNFRs AS
TREATMENT FOR ALZHEIMER’S
DISEASE
Existing therapies that target TNF for clinical use are based on
monoclonal antibodies that inhibit its signaling via its receptors.
These therapies have been approved for treatment of several
inflammatory and autoimmune diseases, including rheumatoid
arthritis, psoriatic arthritis or plaque psoriasis. The therapeutic
potential of these anti-TNF antibodies has more recently been
studied in neurodegenerative diseases. Infliximab is a chimeric
IgG1 monoclonal antibody that has a high binding affinity for
human TNF. Two similar studies that were performed in AD
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mouse models showed that intracerebroventricular injection of
infliximab reduced tau phosphorylation, TNF levels and Aβ
plaques (Shi et al., 2011a), and improved visual recognition
memory (Kim et al., 2016). Furthermore, intrathecal treatment
of infliximab in a female case with AD showed a significant
improvement in cognition (Shi et al., 2011b).
Another biologic anti-TNF drug is etanercept, a combination
of the extracellular domain of TNFR2 linked to the Fc portion
of a human IgG1. A pilot study conducted in 15 AD patients
that received perispinal administration of etanercept resulted in
a reduction of cognitive deficits based on the AD Assessment
Scale-Cognitive Subscale, the Severe Impairment Battery, and
the Mini-Mental State Examination (Tobinick et al., 2006).
A follow-up study by the same research group (Tobinick
and Gross, 2008) reported a significant cognitive improvement
in one AD patient within minutes after perispinal treatment
with etanercept. Moreover, treatment of etanercept in an AD
mouse model resulted in enhanced cognition as well as a
reduction in the hippocampal levels of TNF (Detrait et al.,
2014). Additionally, an experiment performed in rats showed
that peripheral administration of labeled etanercept is able to
penetrate in the CNS (Tobinick et al., 2009), whereas a later
similar study in rats reported no penetration of labeled etanercept
when injected into the perispinal area (Roerink et al., 2015).
These contradicting studies question the mechanism of action of
etanercept.
Another limitation of the abovementioned etanercept studies
in AD patients is that they did not include a control group
receiving placebo and the long-term effects of etanercept were not
stated. In fact, Atigari and Healy (2014) described the appearance
of psychiatric-like symptoms related to schizophrenia in a
patient receiving etanercept with no previous psychiatric history.
Furthermore, Butchart et al. (2015) did not find significant
differences in cognition nor behavior between AD patients
receiving placebo or etanercept in a randomized, placebo-
controlled, double-blind study. Nonetheless, they reported a
higher prevalence of infections in the etanercept group compared
with the placebo group (Butchart et al., 2015). Moreover, Sicotte
and Voskuhl (2001) reported that a patient receiving etanercept
as treatment for rheumatoid arthritis developed multiple sclerosis
and optic neuritis.
The use of a similar biological anti-TNF drug, lenercept,
was unsuccessful as treatment for relapsing-remitting multiple
sclerosis in a placebo-controlled, double-blind phase 2 study.
Indeed, patients receiving lenercept experienced an earlier and
significant aggravation of the disease compared with patients
receiving placebo (Group, 1999). Other studies have also
related TNF blockade with the appearance of autoimmune-like
syndromes, like lupus, neuropathies and demyelinating disorders
(Prinz, 2011). Finally, Deepak et al. (2013) also claimed a relation
between anti-TNF therapies and the development of infections
and neurological events.
These studies collectively show that anti-TNF therapies may
be disadvantageous, especially in the treatment of neurological
diseases. In this respect, total inhibition of TNF might nullify its
positive effects, particularly via its TNFR2. Given the evidence
described, we will focus on new experimental therapies that
selectively interfere with the TNF receptors signaling for the
treatment of neurodegenerative diseases:
Inhibition of TNFR1 by Soluble TNF
Inhibitor
As concluded in the previous section, TNFR1 plays a key role in
neuroinflammation and apoptosis occurring AD. Since solTNF
primarily activates TNFR1, a specific inhibition of solTNF would,
in principle, block the functions of TNFR1 without preventing
the neuroprotective functions of TNFR2.
XPro-1595 is a selective solTNF inhibitor (Figure 2).
Results from animal studies show that XPro-1595 improves
pathologies in models for neurodegenerative diseases. First, in
experimental autoimmune encephalomyelitis (EAE), a multiple
sclerosis model, XPro-1595 improved remyelination and reduced
CNS lesions and neuroinflammation (Brambilla et al., 2011;
Evangelidou et al., 2014). Besides, in a similar study, Taoufik et al.
(2011) demonstrated that inhibition of solTNF by XPro-1595
significantly decreased the levels of pro-inflammatory cytokines
in the brain and protected mice in the context of EAE. A later
study supported the ability of XPro-1595 to ameliorate EAE
symptoms in mice, although, in this case, the presence of TNFR2
in oligodendrocytes was necessary (Madsen et al., 2016). This
study shows that the solely inhibition of solTNF and, thus,
TNFR1 by XPro-1595 might not be sufficient to protect mice
from EAE. Moreover, in mice with spinal cord injury, treatment
with XPro-1595 significantly increased the protein levels of
TNFR2 in the injured area, and enhanced cognition (Novrup
et al., 2014). Likewise, a study on acute spinal cord injury
in rats that were treated with XPro-1595 showed a significant
improvement in immune dysfunction and autonomic dysreflexia
symptoms (Mironets et al., 2018). In a mouse model of cerebral
ischemia, intravenous administration of XPro-1595 improved
motor functions and reduced inflammation (Clausen et al.,
2014). Additionally, in a mouse model of Huntington’s disease,
intracerebroventricular infusion of XPro-1595 resulted in an
improvement of motor functions, increased neuronal viability
and decreased neuroinflammation (Hsiao et al., 2014).
Furthermore, in a recent study using a rat model of Parkinson’s
disease, peripheral injection of XPro-1595 significantly reduced
apoptosis, inflammation, and loss of dopaminergic neurons
(Barnum et al., 2014). This study also demonstrated that XPro-
1595 can effectively reach the brain by crossing the blood–brain
barrier (Barnum et al., 2014). In an AD context, Cavanagh et al.
(2016), showed that XPro-1595 was able to prevent synaptic
loss when treating mice at an early stage. Finally, MacPherson
et al. (2017) showed that systemic administration of XPro-1595
reduced Aβ plaques in the subiculum and restored long-term
potentiation in a mouse model of AD. Overall, these findings
indicate that XPro-1595 is an effective therapy in disease models
where neuroinflammation events are present, suggesting that it
could also be used as a potential therapy to treat AD.
Inhibition of TNFR1 by TNFR1 Antagonist
In addition to inhibition of TNFR1 signaling by removing
its most important ligand solTNF, TNFR1 antagonists may
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FIGURE 2 | Schematic of TNF signaling via its two receptors TNFR1 and TNFR2 as well as the existing potential therapeutic approaches targeting TNFR2, including
solTNF inhibitor [e.g., xPro1595 (Olleros et al., 2010; Shi et al., 2011a)], TNFR1-specific antagonist [e.g., ATROSAB (Kim et al., 2016)], and TNFR2-specific agonists
[e.g., TNF-scTNFR2 (Fischer et al., 2011) and EHD2-scTNFR2 (Dong et al., 2016)]. solTNF, soluble tumor necrosis factor; tmTNF, transmembrane tumor necrosis
factor.
serve to inhibit TNFR1 signaling. To this end, Zettlitz et al.
(2010) generated an antagonistic TNFR1-specific antibody
(ATROSAB), which is able to interfere with the different signaling
pathways of TNFR1 (Figure 2). The efficacy of ATROSAB
has not yet been tested in AD, but it has been assessed
in a nucleus basalis magnocellularis (NBM) chemical lesion
model. This in vivo model is generated by an exposure to
glutamate, which causes neuronal cell death and, mimics acute
neurodegenerative diseases. The NBM lesion model provokes
an activation of macrophages and microglia (inflammation)
and a loss of cholinergic fibers similar to that in AD (Dong
et al., 2016). Treatment with ATROSAB or with a TNFR2
agonist (the latter discussed in the section “Stimulation of
TNFR2 by TNFR2 Agonist”) reverted these symptoms and
protected from memory deficits and excitotoxicity. Besides,
by blocking TNFR1, ATROSAB shifted the TNF signaling
toward TNFR2, and showed to be neuroprotective in this
lesion model (Dong et al., 2016). Importantly, a recent study
that tested ATROSAB in the EAE multiple sclerosis model
demonstrated that treatment with ATROSAB was able to
significantly mitigate EAE symptoms and delay the disease
onset, proving the potential efficacy of ATROSAB in this
neurodegenerative disease model (Williams et al., 2018).
Accordingly, ATROSAB may represent a potential therapy for
treating AD.
Stimulation of TNFR2 by TNFR2 Agonist
Instead of inhibiting TNFR1 signaling in order to prevent cell
death, one can promote the signaling through TNFR2 in order
to stimulate cell survival. The neuroprotective role of TNFR2
signaling has been reported in several studies (Fontaine et al.,
2002; Marchetti et al., 2004; Patel et al., 2012; Maier et al., 2013;
Fischer et al., 2014). Hence, Fischer et al. (2011) developed a
soluble human TNFR2 agonist (TNC-scTNFR2) that selectively
mimics tmTNF, augmenting TNFR2 activation (Figure 2). This
agonist proved to protect against neuronal cell death induced
by oxidative stress (Fischer et al., 2011), which is a common
hallmark of neurodegenerative diseases, including AD. Dong
et al. (2016) evaluated the efficacy of another selective TNFR2
agonist (EHD2-scTNFR2) in combination with ATROSAB in
the NMB lesion model (Dong et al., 2016). This combination
of TNFR1 antagonist and TNFR2 agonist selectively inhibited
TNFR1 and enhanced TNFR2 activation, acquiring a potent
neuroprotective effect, as revealed by an improvement in memory
and cell viability, and a reduction in the loss of cholinergic
fibers and inflammation. Overall, this study (Dong et al., 2016)
demonstrated that the combination of the antagonistic TNFR1-
specific antibody ATROSAB and the selective TNFR2 agonist
EHD2-scTNFR2 is effective to treat an acute neurodegenerative
disorder caused by glutamate-induced excitotoxicity. Thus, it
is plausible that applying this strategy will serve to treat other
neurological disorders, like AD.
CONCLUSION
The discovery of the apparent dual role of TNF through
its two receptors has initiated extensive research into
new possibilities to treat neuroinflammation, a common
hallmark of neurodegenerative diseases. The initial discovery
of anti-TNF therapies led to inconclusive results due to
the potential side effects that were reported. Therefore, the
development of specific TNFR1 antagonists and solTNF
inhibitors (ATROSAB and XPro-1595) that ameliorate
inflammation and apoptosis, and TNFR2 agonists that
enhance neuro-regeneration and tissue homeostasis, are
promising strategies to treat neurodegeneration. As discussed
in this mini-review, a considerable number of studies have
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shown the efficacy of targeting TNF receptors in several
neurodegenerative diseases, suggesting that these drugs might
have potential in the therapy of AD. In the future, a deeper
understanding of the diverse molecular pathways of TNF
signaling can contribute to the discovery of more specific and
refined strategies to treat AD and other neurodegenerative
diseases.
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